Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery

Parodi, Alessandro; Molinaro, Roberto; Sushnitha, Manuela; Evangelopoulos, Michael; Martinez, Jonathan O.; Arrighetti, Noemi; Corbo, Claudia; Tasciotti, Ennio

doi:10.1016/j.biomaterials.2017.09.020

Cited by 216 publications

(158 citation statements)

References 152 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Viruses have evolved to evade immune surveillance and transport genetic material into cells in a highly efficient manner; however, the safety and immunogenicity of viruses remain a subject of conversation . Tremendous effort have been made to modify virus–host interactions through processing or re‐engineering viral vehicles; yet, concern still remains over these approaches .…”

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, such a lack of targeting capacity explains the recent interest in using human cells as drug carriers, to take advantage of the inherent physiological targeting capacity provided by the physiological "decorations" of cell membranes by various glycoproteins [24,30,54,55]. The potential to use, or mimic, circulatory cells as a DDS has been demonstrated in in vitro and in vivo models, providing a tool benefiting from the functional reactivity of cellular membranes, including PLT [23,24,[56][57][58]. Circulatory cells are biocompatible and have long residence times in the blood circulation.…”

Section: Discussionmentioning

confidence: 99%

Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop

Huang

Changou

et al. 2020

J Biomed Sci

View full text Add to dashboard Cite

Background: Human platelets (PLT) and PLT-extracellular vesicles (PEV) released upon thrombin activation express receptors that interact with tumour cells and, thus, can serve as a delivery platform of anti-cancer agents. Drugloaded nanoparticles coated with PLT membranes were demonstrated to have improved targeting efficiency to tumours, but remain impractical for clinical translation. PLT and PEV targeted drug delivery vehicles should facilitate clinical developments if clinical-grade procedures can be developed.Methods: PLT from therapeutic-grade PLT concentrate (PC; N > 50) were loaded with doxorubicin (DOX) and stored at − 80°C (DOX-loaded PLT) with 6% dimethyl sulfoxide (cryopreserved DOX-loaded PLT). Surface markers and function of cryopreserved DOX-loaded PLT was confirmed by Western blot and thromboelastography, respectively. The morphology of fresh and cryopreserved naïve and DOX-loaded PLT was observed by scanning electron microscopy. The content of tissue factor-expressing cancer-derived extracellular vesicles (TF-EV) present in conditioned medium (CM) of breast cancer cells cultures was measured. The drug release by fresh and cryopreserved DOX-loaded PLT triggered by various pH and CM was determined by high performance liquid chromatography. The thrombin activated PEV was analyzed by nanoparticle tracking analysis. The cellular uptake of DOX from PLT was observed by deconvolution microscopy. The cytotoxicities of DOX-loaded PLT, cryopreserved DOX-loaded PLT, DOX and liposomal DOX on breast, lung and colon cancer cells were analyzed by CCK-8 assay.(Continued on next page) Results: 15~36 × 10 6 molecules of DOX could be loaded in each PLT within 3 to 9 days after collection. The characterization and bioreactivity of cryopreserved DOX-loaded PLT were preserved, as evidenced by (a) microscopic observations, (b) preservation of important PLT membrane markers CD41, CD61, protease activated receptor-1, (c) functional activity, (d) reactivity to TF-EV, and (e) efficient generation of PEV upon thrombin activation. The transfer of DOX from cryopreserved PLT to cancer cells was achieved within 90 min, and stimulated by TF-EV and low pH. The cryopreserved DOX-loaded PLT formulation was 7~23-times more toxic to three cancer cells than liposomal DOX.Conclusions: Cryopreserved DOX-loaded PLT can be prepared under clinically compliant conditions preserving the membrane functionality for anti-cancer therapy. These findings open perspectives for translational applications of PLT-based drug delivery systems.

show abstract

“…[19] Sophisticated engineering of these cell membrane characteristics facilitates nanocarriers to favorably accumulate in the target tissue. [21] Promising results have emerged recently in molecular imaging, drug delivery and immune therapy. [21] Promising results have emerged recently in molecular imaging, drug delivery and immune therapy.…”

Section: Introductionmentioning

confidence: 99%

Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation

et al. 2019

View full text Add to dashboard Cite

Inflammation is ubiquitous in the body, triggering desirable immune response to defend against dangerous signals or instigating undesirable damage to cells and tissues to cause disease. Nanomedicine holds exciting potential in modulating inflammation. In particular, cell membranes derived from cells involved in the inflammatory process may be used to coat nanotherapeutics for effective targeted delivery to inflammatory tissues. Herein, the recent progress of rationally engineering cell membrane‐based nanotherapeutics for inflammation therapy is highlighted, and the challenges and opportunities presented in realizing the full potential of cell‐membrane coating in targeting and manipulating the inflammatory microenvironment are discussed.

show abstract

Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery

Cited by 216 publications

References 152 publications

Materials for Immunotherapy

Materials for Immunotherapy

Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop

Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation

Contact Info

Product

Resources

About